Jump to content

Gene patents in the United States: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
corrected last edits to lede
→Myriad Genetics case: added wikilink to replace "ineliglible"
Line 40: Line 40:
''[[Association for Molecular Pathology v. Myriad Genetics]]'' [[Docket (court)|No. 11-725]] is a case challenging the [[Patentable subject matter|validity]] of [[gene patent]]s in the United States, specifically challenging certain claims in issued [[patent]]s owned or controlled by [[Myriad Genetics]] that cover [[DNA extraction|isolated DNA]] sequences, methods to diagnose propensity to cancer by looking for mutated [[DNA]] sequences, and methods to identify drugs using isolated DNA sequences.
''[[Association for Molecular Pathology v. Myriad Genetics]]'' [[Docket (court)|No. 11-725]] is a case challenging the [[Patentable subject matter|validity]] of [[gene patent]]s in the United States, specifically challenging certain claims in issued [[patent]]s owned or controlled by [[Myriad Genetics]] that cover [[DNA extraction|isolated DNA]] sequences, methods to diagnose propensity to cancer by looking for mutated [[DNA]] sequences, and methods to identify drugs using isolated DNA sequences.


The case was originally heard in the [[United States District Court for the Southern District of New York]], which ruled that all the challenged claims were not patent eligible. Myriad then appealed to the [[United States Court of Appeals for the Federal Circuit]]. The Circuit court overturned the previous decision in part, ruling that isolated DNA which does not exist alone in nature ''can'' be patented and that the drug screening claims were valid, and confirmed in part, finding the diagnosic claims unpatentable. The plaintiffs appealed to the Supreme Court, which granted cert and remanded the case back to the Federal Circuit. The Federal Circuit did not change its opinion, so on September 25, 2012, the American Civil Liberties Union and the Public Patent Foundation filed a petition for certiorari with the Supreme Court with respect to the second Federal Circuit Decision. As of December 2012 isolated genes remain patentable in the US.
The case was originally heard in the [[United States District Court for the Southern District of New York]], which ruled that all the challenged claims were not [[patentable subject matter]]. Myriad then appealed to the [[United States Court of Appeals for the Federal Circuit]]. The Circuit court overturned the previous decision in part, ruling that isolated DNA which does not exist alone in nature ''can'' be patented and that the drug screening claims were valid, and confirmed in part, finding the diagnosic claims unpatentable. The plaintiffs appealed to the Supreme Court, which granted cert and remanded the case back to the Federal Circuit. The Federal Circuit did not change its opinion, so on September 25, 2012, the American Civil Liberties Union and the Public Patent Foundation filed a petition for certiorari with the Supreme Court with respect to the second Federal Circuit Decision. As of December 2012 isolated genes remain patentable in the US.


On November 30, 2012, the [[Supreme Court of the United States|Supreme Court]] agreed to hear the plaintiffs' appeal of the Federal Circuit's ruling. It is anticipated that the court will rule on whether isolated genes are patentable.<ref>{{cite web |title=Supreme Court Grants Myriad’s Petition for Cert. |url=http://www.natlawreview.com/article/supreme-court-grants-myriad-s-petition-cert|publisher=Schwegman, Lundberg & Woessner, P.A. |work=The National Law Review|date=December 3, 2012|accessdate=December 5, 2012}}</ref>
On November 30, 2012, the [[Supreme Court of the United States|Supreme Court]] agreed to hear the plaintiffs' appeal of the Federal Circuit's ruling. It is anticipated that the court will rule on whether isolated genes are patentable.<ref>{{cite web |title=Supreme Court Grants Myriad’s Petition for Cert. |url=http://www.natlawreview.com/article/supreme-court-grants-myriad-s-petition-cert|publisher=Schwegman, Lundberg & Woessner, P.A. |work=The National Law Review|date=December 3, 2012|accessdate=December 5, 2012}}</ref>

Revision as of 00:14, 11 December 2012

Patent law
Overviews
Procedural concepts
Patentability requirements and related concepts
Other legal requirements
By region / country
By specific subject matter
See also

A gene patent is a patent on a specific isolated gene sequence, its chemical composition, the processes for obtaining or using it, or a combination of such claims. With respect to subject matter, gene patents may be considered a subset of the broader category of biological patents. As with all utility patents in the U.S, the patent provides the patent holder with the right to exclude others from making, using, selling, or importing the claimed invention for a limited period of time - for patents filed after 1998, twenty years from the filing date.[1]

Gene patents may claim the isolated natural sequences of genes, the use of a natural sequence for purposes such as diagnostic testing, or a natural sequence that has been altered by adding a promoter or other changes to make it more useful. In the United States, patents on genes have only been granted on isolated gene sequences with known functions, and these patents cannot be applied to the naturally occurring genes in humans or any other naturally occurring organism.[2]

History

The United States has been patenting chemical compositions based upon human products for over 100 years. The first patent for a human product was granted on March 20, 1906 for a purified form of adrenaline. It was challenged and upheld in Parke-Davis v. Mulford [3] Judge Hand argued that natural substances when they are purified are more useful than the original natural substances. [4]

In 1980, the U.S. Supreme Court, in Diamond v. Chakrabarty, upheld the first patent on a newly created living organism, a bacterium for digesting crude oil in oil spills. The patent examiner for the United States Patent and Trademark Office had rejected the patent of a living organism, but Chakrabarty appealed. As a rule, raw natural material is generally rejected for patent approval by the USPTO. The Court ruled that as long as the organism is truly "man-made," such as through genetic engineering, then it is patentable. Because the DNA of Chakrabarty's organism was modified, it was patentable.

Examples

The "Chakrabarty patent", owned by General Electric, was filed in 1972 and issued in 1981 after the Supreme Court decision discussed above.[5] While not commercially important,[6] this patent and the Supreme Court case "opened the floodgates for protection of biotechnology-related inventions and helped spark the growth of an industry."[7]

In 1978 University of California filed a patent application for the cDNA encoding human growth hormone, which issued in 1982 as US Patent 4,363,877 and listed Howard M. Goodman, John Shine, and Peter H. Seeburg as inventors.[8] University of California licensed its patent to Lilly, leading to extended litigation among University of California, Lilly, and Genentech; each of Lilly and Genentech had introduced recombinant human growth hormone drugs, which were among the first biotech drugs brought to market.[6]

The "Cohen/Boyer patents" were invented by Stanley Cohen of Stanford University and Herbert Boyer of University of California, San Francisco.[9][10][11] The patents cover inventions for splicing genes to make recombinant proteins that are foundational to the biotechnology industry.[12] Stanford managed the patents and licensed them nonexclusively and broadly, earning over $200 million for the universties.[12][13]

The "Axel Patents" were invented by Richard Axel,Michael H. Wigler, and Saul J. Silverstein of Columbia University.[14][15][16][17][18][19] These patents covered cotransformation, a form of transformation, another foundational method of biotechnology; Columbia licensed these patents nonexclusively and broadly and earned about $790 million.[19]

Key methods to manipulate DNA to create monoclonal antibodies are covered by a thicket of patents,[20] including the "Winter patent" was invented by Gregory P. Winter of the Medical Research Council[21] which covers methods to make chimeric, humanized antibodies and has been licensed to about fifty companies.[22] Abgenix owned a patent on methods of making transgenic mice lacking endogenous heavy chains.[23][20] The "Boss patent" was owned by Celltech[24] and covered methods of making recombinant antibodies and antibody fragments, together with vectors and host cells useful in these processes.[20] Genentech owned the "Old Cabilly" patent[25] that covered altered and native immunoglobulins prepared in recombinant cell culture, as well as the "New Cabilly" patent[26] that covers artificial synthesis of antibody molecules.[20] Medarex owned a patent[27] that covered high affinity human antibodies from transgenic mice.[20] These patents have been broadly licensed and have been the subject of litigation among patent holders and companies that have brought monoclonal antibody drugs to market.[20]

A patent application for the isolated BRCA1 gene and cancer-cancer promoting mutations, as well as methods to diagnose the likelihood of getting breast cancer, was filed by the University of Utah, National Institute of Environmental Health Sciences (NIEHS) and Myriad Genetics in 1994;[28] over the next year, Myriad, in collaboration with investigators from Endo Recherche, Inc., HSC Research & Development Limited Partnership, and University of Pennsylvania, isolated and sequenced the BRCA2 gene, and the first BRCA2 patent was filed in the U.S. by Myriad and other institutions in 1995.[29] Currently holding 9 patens in total for the BRCA1 and BRCA2 genes, Myriad is the exclusive licensee of these patents and has enforced them in the US against clinical diagnostic labs.[30] This means that legally all testing must be done through Myriad's lab or by a lab which it had licensed. This business model led from Myriad being a startup in 1994 to being a publicly-traded company with 1200 employees and about $500M in annual revenue in 2012[31]; it also led to controversy and the Association for Molecular Pathology v. Myriad Genetics lawsuit mentioned below.[30] The patents expire, starting in 2014.

Controversy

Law professor Rebecca S. Eisenberg argues that gene patents produce an "anticommons" at odds with an ideal scientific commons.[32]

Others claim that patents have not created this "anticommons" effect on research, based on surveys of scientists.[33][34]

Professional societies of pathologists have criticized patents on disease genes and exclusive licenses to perform DNA diagnostic tests. In the 2009 Myriad case, doctors and pathologists complained that the patent on BRCA1 and BRCA2 genes prevented patients from receiving second opinions on their test results. Pathologists complained that the patent prevented them from carrying out their medical practice of doing diagnostic tests on patient samples and interpreting the results.[35]

Another example is a series of lawsuits filed by the Alzheimer’s Institute of America (AIA) starting in 2010, concerning a gene patent it controls. The patent covers a genetic mutation that predisposes to Alzheimer's, and more importantly, it applies to transgenic mice carrying the mutation. These mice are widely used in Alzheimer's research, both by academic scientists doing basic research and by companies that use the mice to test products in development. Two of these suits are directed to companies that were started based on inventions made at universities (Comentis and Avid), and in each of those cases, the university has been sued along with the company. While none of the suits target universities that are conducting basic research using the mice, one of the suits is against Jackson Labs, a nonprofit company that provides transgenic mice to academic and commercial researchers and is an important repository of such mice.[36]

While there is some controversy concerning the patenting of isolated genes and the way those patents are used, and there is controversy concerning patents on the diagnostic uses of genes (the real source of dispute in the Myriad court case), it is difficult to find controversy surrounding patents on genes that are used to manufacture therapeutic proteins (for an example of patents on therapeutic proteins, the drug candidate that is the subject of the early part of the movie 'Extraordinary Measures' was covered in part by a classic gene patent, US Patent 6,770,468.[1]) There is also little controversy concerning the role of gene patents in the chemical industry—for instance in the manufacture of enzymes used in consumer products or industrial processes.[2]

Myriad Genetics case

Main article: Association for Molecular Pathology v. Myriad Genetics

Association for Molecular Pathology v. Myriad Genetics No. 11-725 is a case challenging the validity of gene patents in the United States, specifically challenging certain claims in issued patents owned or controlled by Myriad Genetics that cover isolated DNA sequences, methods to diagnose propensity to cancer by looking for mutated DNA sequences, and methods to identify drugs using isolated DNA sequences.

The case was originally heard in the United States District Court for the Southern District of New York, which ruled that all the challenged claims were not patentable subject matter. Myriad then appealed to the United States Court of Appeals for the Federal Circuit. The Circuit court overturned the previous decision in part, ruling that isolated DNA which does not exist alone in nature can be patented and that the drug screening claims were valid, and confirmed in part, finding the diagnosic claims unpatentable. The plaintiffs appealed to the Supreme Court, which granted cert and remanded the case back to the Federal Circuit. The Federal Circuit did not change its opinion, so on September 25, 2012, the American Civil Liberties Union and the Public Patent Foundation filed a petition for certiorari with the Supreme Court with respect to the second Federal Circuit Decision. As of December 2012 isolated genes remain patentable in the US.

On November 30, 2012, the Supreme Court agreed to hear the plaintiffs' appeal of the Federal Circuit's ruling. It is anticipated that the court will rule on whether isolated genes are patentable.[37]

See also

References

  1. ^ Cook-Deegan, Robert. "Gene patents". The Hastings Center. Retrieved 10 December 2012.
  2. ^ "Federal Register - Utility Examination Guidelines - Comments and Responses". January 5, 2001. Retrieved April 5, 2010. See Comment 2 in which this objection is specifically raised and addressed.
  3. ^ Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95 (C.C.S.D.N.Y. 1911), Learned Hand, J.
  4. ^ Dutfield, Graham. "DNA Patenting: Implications for Public Health Research." Bulletin of the World Health Organization, May 2006, Volume 85, Issue 5.
  5. ^ Chakrabarty - US Patent 4,259,444
  6. ^ a b Matthew RImmer. (2002/2003) Genentech and the Stolen Gene: Patent Law and Pioneer Inventions Bio-Science Law Review 5(6):198-211
  7. ^ Douglas Robinson and Nina Medlock (2005) Diamond v. Chakrabarty: A Retrospective on 25 Years of Biotech Patents. Intellectual Property & Technology Law Journal 17(10):12-15
  8. ^ US Patent 4,363,877
  9. ^ US Patent 4,237,224
  10. ^ US Patent 4,468,464
  11. ^ US Patent 4,740,470
  12. ^ a b Feldman MP, A Colaianni and C Liu. 2007. [http://www.iphandbook.org/handbook/chPDFs/ch17/ipHandbook-Ch%2017%2022%20Feldman-Colaianni0Liu%20Cohen-Boyer%20Patents%20and%20Licenses.pdf Lessons from the Commercialization of the Cohen-Boyer Patents: The Stanford University Licensing Program. In Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices (eds. A Krattiger, RT Mahoney, L Nelsen, et al.). MIHR: Oxford, U.K., and PIPRA: Davis, U.S.A. Available online at www.ipHandbook.org.
  13. ^ Chris Rauber for the San Francisco Business Times. November 23, 1997. $200M patent runs out
  14. ^ U.S. Patent 4,399,216
  15. ^ U.S. Patent 4,634,665
  16. ^ U.S. Patent 5,179,017
  17. ^ U.S. Patent 5,149,636
  18. ^ U.S. Patent 6,455,275
  19. ^ a b Alessandra Colaianni and Robert Cook-Deegan (2009) Columbia University's Axel Patents: Technology Transfer and Implications for the Bayh-Dole Act Milbank Q.87(3): 683–715.
  20. ^ a b c d e f Jennifer van Brunt (2005) The Monoclonal Maze Signals Online Magazine
  21. ^ US Patent 5,225,539
  22. ^ MRC Official Website Achievements and Impact: Therapeutic Antibodies
  23. ^ US Patent 5,939,598
  24. ^ US Patent 4,816,397
  25. ^ US Patent 4,816,567
  26. ^ US Patent 6,331,415
  27. ^ US Patent 5,770,429
  28. ^ US5747282
  29. ^ US5837492
  30. ^ a b John Schwartz for the New York Times. May 12, 2009. Cancer Patients Challenge the Patenting of a Gene
  31. ^ Myriad Investor Page—see "Myriad at a glance" accessed October 2012
  32. ^ http://journals.lww.com/academicmedicine/fulltext/2002/12001/why_the_gene_patenting_controversy_persists.9.aspx
  33. ^ http://www.thehastingscenter.org/Publications/BriefingBook/Detail.aspx?id=2174
  34. ^ Science Progress Blog
  35. ^ "Association For Molecular Pathology, et al., vs. United States Patent and Trademark Office, et al" (PDF). The New York Times. March 29, 2010. Retrieved March 30, 2010.
  36. ^ Patent dispute threatens US Alzheimer's research; Lawsuit could expose hundreds of scientists to property-rights litigation. Erika Check Hayden, 5 April 2011, Nature 472, 20 (2011) | doi:10.1038/472020a
  37. ^ "Supreme Court Grants Myriad's Petition for Cert". The National Law Review. Schwegman, Lundberg & Woessner, P.A. December 3, 2012. Retrieved December 5, 2012.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Gene_patents_in_the_United_States&oldid=527439790"